Published:Â September 19th 2024Â |Â Updated:Â September 26th 2024
Final Thoughts: The Importance of Comparative Studies in AD
Published:Â June 9th 2025Â |Â Updated:Â June 11th 2025
Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria
Published:Â June 7th 2025Â |Â Updated:Â June 11th 2025
Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD
Published:Â November 9th 2023Â |Â Updated:Â June 11th 2025
Evaluating Stress Levels in AD Treatment Plans
Published:Â June 7th 2025Â |Â Updated:Â June 11th 2025
Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis
Published:Â June 8th 2025Â |Â Updated:Â June 11th 2025
Late-Breaking Data: Real-World Data From Canada Shows Upadacitinib Is Effective in Patients With Moderate to Severe AD With Inadequate Response to Dupilumab